PEDIATRIC INFECTIOUS DISEASE JOURNAL, cilt.18, sa.8, ss.694-697, 1999 (SCI-Expanded)
Background. More than 50% of children with chronic hepatitis B infection do not respond to interferon-alpha (IFN-alpha) treatment and are prone to have progressive liver disease. The best treatment modality is unknown in these children. The aim of this study was to evaluate the possible benefit of a second higher dose IFN-alpha therapy for children with chronic hepatitis B diseases who failed previous therapy.